← Back to Search

Retinal Prosthesis

Predicting the perceptual experience of retinal prosthesis patients for Retinitis Pigmentosa

N/A
Waitlist Available
Led By Michael Beyeler, PhD
Research Sponsored by University of California, Santa Barbara
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial will test how well patients with a retinal prosthesis can see after being given visual percepts either by electrode stimulation or by having them view a computer/projector screen.

Eligible Conditions
  • Retinitis Pigmentosa
  • Visual Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pattern discrimination accuracy
Phosphene brightness relative to reference stimulus
Phosphene shape
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Predicting the perceptual experience of retinal prosthesis patientsExperimental Treatment1 Intervention
This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Argus II
2022
N/A
~70

Find a Location

Who is running the clinical trial?

University of MinnesotaOTHER
1,388 Previous Clinical Trials
1,552,757 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
438 Patients Enrolled for Retinitis Pigmentosa
National Eye Institute (NEI)NIH
547 Previous Clinical Trials
1,401,973 Total Patients Enrolled
23 Trials studying Retinitis Pigmentosa
14,301 Patients Enrolled for Retinitis Pigmentosa
University of California, Santa BarbaraLead Sponsor
28 Previous Clinical Trials
2,935 Total Patients Enrolled
~21 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top